Name

TT-R

Alternate names

None

Primary Site

None

Histology

None

Radiation

None

Remarks

None

Drugs for TT-R

Name

Alternate Names

11C topotecan
Hycamtin
SKF-104864
Topotecan Hydrochloride

Abbreviations

SKFS

Category

Chemotherapy

Subcategory

Topoisomerase inhibitor

NSC Number

609699

Primary Site

cervix
Colorectal
leukemia
lung
ovarian cancer
small cell lung

Histology

None

Remarks

Phase II (colorectal, NSCLC) Phase II/III SCLC Phase III MDS, ovarian Topoisomerase I inhibitor. FDA approved use on small cell lung cancer and ovarian cancer. GlaxoSmithKline.

Coding

This drug should be coded

Name

Alternate Names

Anti-CD20 monoclonal antibodies
C2B8 monoclonal antibody
IDEC-C2B8
MabThera
Monoclonal antibody IDEC-C2B8
Rituxan

Abbreviations

None

Category

Biologic therapy (BRM, immunotherapy)

Subcategory

Cytostatic monoclonal antibody

NSC Number

687451

Primary Site

Leukemia
NHL

Histology

None

Remarks

December 2, 2021 The FDA approved rituximab (Rituxan, Genentech, Inc.) in combination with chemotherapy for pediatric patients (≥6 months to <18 years) with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL).

JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, Rituximab is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code Rituximab as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding as chemotherapy.

FDA approved 2/2006 for treatment of diffuse large B-cell, CD-20 positive non-Hodgkin lymphoma.

FDA approved 9/2006 for non-Hodgkin's B-cell lymphoma. Also used to treat autoimmune disorders, hemolytic anemia and ITP.

FDA approved 2/2010 for use in combination with cyclophosphamide and fludarabine in treatment of CLL.

FDA approved for maintenance therapy for previously untreated follicular CD-20 positive B-cell non-Hodgkin lymphoma who achieved response to rituximab in combination with chemotherapy.

June 22, 2017 FDA granted regular approval to the combination of rituximab and hyaluronidase human (RITUXAN HYCELA) for adult patients with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.


.

Coding

This drug should be coded

Name

Alternate Names

BMS-181339-01
BMY-45622
Taxol

Abbreviations

None

Category

Chemotherapy

Subcategory

Mitotic inhibitor
plant alkaloid
Taxane

NSC Number

125973
673089

Primary Site

breast
Gastric
head & neck cancer
Kaposi's sarcoma
non-small cell lung cancers
ovarian

Histology

None

Remarks

Phase I (gastric) FDA approved uses on breast, ovarian, non-small cell lung cancers, and Kaposi's sarcoma. Bristol-Myers Squibb.

Coding

This drug should be coded
Glossary